Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use VARUBI safely and effectively. See full prescribing information for VARUBI. VARUBI® (rolapitant) tablets, for oral useInitial U.S. Approval: 2015
Medication labelWhy this: Advisory · dailymed-prescription
VARUBI® is indicated in combination with other antiemetic agents in adults for the prevention of delayed nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy.
- generic_name
- rolapitant
- product_names
- rolapitant
- ndc
- 87628-101, 87628-101-02
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en